Compare McKesson Corporation (MCK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? McKesson Corporation trades at $886.42 (market cap $105.14B), while State Street SPDR S&P Biotech ETF trades at $158.79. The key difference: McKesson Corporation pays a 0.42% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | XBI | |
|---|---|---|
Market Cap | $105.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $164.28 |
52-Week Low | $659.01 | $86.92 |
Enterprise Value | $111.67B | — |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
